Loading
A phase 3 trial of Cabozantinib in renal cell carcinoma, run by Arcus Biosciences, Inc., now recruiting.
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma is a phase 3 interventional study registered as NCT07011719 by Arcus Biosciences, Inc., with 720 participants planned, started 2025-09-08 and due to reach its primary completion in 2028-04. Interventions recorded: Casdatifan, Cabozantinib, Placebo. Conditions listed: Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Clear cell renal cell carcinoma, Cabozantinib, Anti-angiogenic therapy, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Anti-angiogenic therapy, Renal cell carcinoma, Small-molecule kinase inhibitors.
Shares Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Cabozantinib, Anti-angiogenic therapy, Renal cell carcinoma, Small-molecule kinase inhibitors.
Shares Clear cell renal cell carcinoma, Anti-angiogenic therapy, Renal cell carcinoma, Small-molecule kinase inhibitors.
Shares Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/